Email this article The issues of treatment of primary refractory and relapse patients with diffuse large B-cell lymphoma in the Russian Federation. What awaits us in the future?
- Authors: - -
- Issue: Vol 21, No 3 (2019)
- Pages: 6-8
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33501
- DOI: https://doi.org/10.26442/18151434.2019.3.190660
- ID: 33501
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- Teras L.R, DeSantis CE, Cerhan J.R et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016.
- Tilly H, Vitolo U, Walewski J et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): vii78-82.
- Бабичева Л.Г. ДВККЛ: данные регистра Российского общества онкогематологов, Москва, Консультационный совет «Проблемы терапии первично-рефрактерных и рецидивных пациентов с диффузной В-крупноклеточной лимфомой в Российской Федерации. Что ждет нас в будущем?» Москва, 27 июня 2019 г. @@Babicheva L.G. DVKKL: dannye registra Rossiiskogo obshchestva onkogematologov, Moskva, Konsul'tatsionnyi sovet "Problemy terapii pervichno-refrakternykh i retsidivnykh patsientov s diffuznoi V-krupnokletochnoi limfomoi v Rossiiskoi Federatsii. Chto zhdet nas v budushchem?" Moskva, 27 iiunia 2019 g. (in Russian)
- Доронин В.А., Стефанов Д.Н., Никитин Е.А. и др. Раковые регистры. Часть 4. Российский регистр «Лимфопролиферативные заболевания». Современная Онкология. 2012; 14 (4): 15-6. @@Doronin V.A., Stefanov D.N., Nikitin E.A. et al. Cancer registries. Part 4. Russian lymphoproliferative disease registry. Journal of Modern Oncology. 2012; 14 (4): 15-6 (in Russian)
- Каприн А.Д. и др. Злокачественные новообразования в России. М., 2018. @@Kaprin A.D. et al. Malignant neoplasms in Russia. Moscow, 2018 (in Russian).]
- Суборцева И.Н. Клинико-биологические особенности первичной экстранодальной диффузной В-крупноклеточной лимфомы. М., 2012. @@Subortseva I.N. Clinical and biological features of primary extranodal diffuse B-large cell lymphoma. Moscow, 2012 (in Russian)
- Shipp M.A Crump et al. SCHOLAR-1 Manuscript Blood lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30 (36): 4462-9.
- Капланов К.Д. и др. Результаты анализа регионального регистра пациентов с диффузной В-крупноклеточной лимфомой: факторы риска и проблемы иммунохимиотерапии. Clin Oncohematol 2019; 12 (2): 154-64. @@Kaplanov K.D. et al. Rezul'taty analiza regional'nogo registra patsientov s diffuznoi V-krupnokletochnoi limfomoi: faktory riska i problemy immunokhimioterapii. Clin Oncohematol 2019; 12 (2): 154-64 (in Russian)
- Younes A et al. Randomized Phase III Trial of Ibrutinib and RCHOP in non-GCB DLBCL. J Clin Oncol 2019; 37 (15): 1285-95.
- Vitolo U et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated DLBCL. J Clin Oncol 2017; 35: 3529-37.
- Vitolo U et al. ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematological Oncology, Supplement, 15th ICML congress. 2019; 37 (Issue S2): 36-7.
- Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130 (16): 1800-8.
- Nagle S.J, Woo K, Schuster S.J et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013; 88 (10): 890-4.
- Kochenderfer J.N, Rosenberg S.A. Treating B-cell cancer with T cells expressing antiCD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10 (5): 267-76.
- Sehn L et al. Abstract #1683, ASH 2018.
- Sehn L et al. Abstract #202, ICML 2019.
- https://www.roche.com/media/releases/med-cor-2019-06-11b.htm
